Article: Nicotinamide Riboside Supplementation Reduces Inflammation in Heart Failure Patients: Clinical Findings

Aug 13, 2020 Cardiovascular Disease Cardiovascular Health Clinical Inflammation

Nicotinamide Riboside Supplementation Reduces Inflammation in Heart Failure Patients: Clinical Findings

Objectives

To investigate the mechanistic link between mitochondrial dysfunction and inflammatory activation in peripheral blood mononuclear cells (PBMCs), and the potential antiinflammatory effect of boosting NAD+ levels.

Journal

Journal of Clinical Investigation

Key Outcomes

NR supplementation increased whole blood NAD+ levels and mitochondrial respiration rate of the heart failure patients' PBMCs.
NR reduced the production and gene expression of proinflammatory cytokines.
The systemic inflammation in heart failure patients was causally linked to mitochondrial function of the PBMCs.

Duration

5-9 days

Dose

2000 mg

Study Design

Ex vivo and pilot clinical study in 5 Stage D heart failure patients

See Published Study

Pharmacokinetic/Safety

Nicotinamide Riboside: Review

SynopsisNicotinamide riboside (NR) is a well-studied NAD+ precursor with multiple health benefits linked to increasing NAD+ levels in the body. Studies in animals and humans show NR may help treat ...

Ataxia Telangiectasia

Nicotinamide Riboside Supplementation Enhances NAD+ Metabolism in Ataxia Telangiectasia: Clinical Findings

Objectives To study the metabolic effects of treatment with NR in a cohort of patients with ataxia-telangiectasia (AT). Journal Metabolites Key Outcomes NR-related pathways and metabolites signi...